期刊文献+

TACE联合阿帕替尼治疗中晚期肝癌的临床研究 被引量:5

Transcatheter arterial chemoembolization combined with apatinib for the treatment of advanced liver cancers:a clinical study
下载PDF
导出
摘要 目的观察单纯肝动脉栓塞化疗(TACE)治疗与TACE联合阿帕替尼治疗中晚期肝癌的临床疗效及安全性。方法回顾性分析2017年3月至2018年10月收治的40例肝癌切除术后出现残癌或复发灶的患者的病历资料,采用TACE联合阿帕替尼治疗,作为观察组。并收集同期采用单纯TACE治疗的同类患者40例作为对照组。比较两组患者的治疗效果、不良反应、AFP水平及生存情况。结果观察组的客观缓解率(ORR)为47.5%,较对照组(25.0%)明显提高(P<0.05)。观察组高血压、皮肤反应的发生率明显高于对照组(P<0.05)。两组患者治疗后3个月的AFP水平均较治疗前显著降低(P<0.05),观察组治疗后3个月的AFP水平较对照组显著降低(P<0.05)。12个月随访结束时,对照组生存11例、死亡29例,观察组生存22例、死亡18例,对照组中位生存时间为11个月,观察组生存时间尚无法估算,情况显著优于对照组(P<0.05)。结论TACE联合阿帕替尼治疗中晚期肝癌较单纯TACE治疗效果好,不良反应可控制。 Objective To investigate the clinical efficacy and safety of transcatheter arterial chemoembolization(TACE)combined with apatinib in treating advanced liver cancers.Methods The clinical data of 40 patients with residual cancer tissue or recurrence after liver cancer resection(study group),who were admitted to authors’hospital during the period from March 2017 to October 2018 to receive TACE combined with apatinib therapy,were retrospectively analyzed.Other 40 patients with residual cancer tissue or recurrence after liver cancer resection,who were admitted to authors’hospital during the same period as above to receive pure TACE therapy,were collected and used as control group.The curative effect,adverse reactions,alpha fetoprotein(AFP)levels and survival were compared between the two groups.Results The objective remission rate(ORR)in the study group was 47.5%,which was significantly higher than 25% in the control group(P<0.05).The incidences of hypertension and skin reaction in the study group was prominently higher than that in the control group(P<0.05).In both groups,the postoperative 3-month AFP levels were remarkably decreased when compare with the preoperative ones(P<0.05),but the postoperative 3-month AFP level in the study group was significantly lower than that in the control group(P<0.05).At the end of 12-month follow-up,in the control group 11 patients survived and 29 patients died,while in the study group 22 patients survived and 18 patients died.The median survival time in the control group was 11 months,and the survival rate in the study group was significantly better than that in the control group(P<0.05).Conclusion For the treatment of advanced liver cancers,TACE combined with apatinib is more effective than pure TACE,and its adverse reactions are manageable.
作者 韩绪生 凌冰 杨勇 乔风雷 赵东波 HAN Xusheng;LING Bing;YANG Yong;QIAO Fenglei;ZHAO Dongbo(Department of Intervention,Affiliated Suqian Hospital of Xuzhou Medical University,Suqian,Jiangsu Province 223800,China)
出处 《介入放射学杂志》 CSCD 北大核心 2021年第9期941-944,共4页 Journal of Interventional Radiology
关键词 肝动脉栓塞化疗 阿帕替尼 中晚期肝癌 疗效评价 transcatheter arterial chemoembolization apatinib advanced liver cancer therapeutic evaluation
  • 相关文献

参考文献9

二级参考文献41

共引文献685

同被引文献44

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部